Keywords: ligand, 2nd-qtr, revenues, up, despite, loss, growth
Ligand's 2nd-qtr revenues up 10%, despite 15% loss growth
Article | 19 August 2002
USA-based Ligand Pharmaceuticals has reported revenues of $19.2 millionfor the second quarter of 2002, ended June 30, up 10% from last year's like period. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
